Condition
Solid Tumors Refractory To Standard Therapy
Total Trials
4
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Recruiting3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06940349Phase 1RecruitingPrimary
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
NCT06911333Phase 1Recruiting
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
NCT06883539Phase 1Recruiting
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
NCT00031031Phase 1CompletedPrimary
Kanglaite Injection Phase I Study
Showing all 4 trials